<DOC>
	<DOCNO>NCT01731652</DOCNO>
	<brief_summary>This Phase II pilot study explore effect intravesical TMX-101 patient CIS bladder cancer , assess histology cytology TMX-101 treatment .</brief_summary>
	<brief_title>Study With TMX-101 Patients With Carcinoma In Situ ( CIS ) Bladder Cancer</brief_title>
	<detailed_description>This study open label , pilot study TMX-101 treatment carcinoma situ . TMX-101 new formulation Imiquimod optimize intravesical delivery . Imiquimod possess immune-stimulatory property . TMX-101 develop potential treatment patient non-invasive bladder cancer , include patient CIS bladder cancer . Following confirmation CIS histology , patient receive weekly instillation TMX-101 6 week . Five seven week last instillation , biopsy cytology perform . Response treatment determine base cytology tissue sample histology finding .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<criteria>1 . Males female patient age ≥18 year . 2 . Pathologicallyproven , recurrent , primary , secondary concomitant carcinoma situ disease , define either Ta T1 CIS , CIS alone . In case T1 tumor lesion , muscularis propria tissue resect specimen confirm tumorfree . 3 . Patient undergone mapping bladder Days 28 14 , least one biopsy provide pathological confirmation CIS bladder . Slides must available central pathology review . 4 . Patient undergone bladder wash cytology Days 28 1 . In patient Ta T1 lesion ( ) resect , bladder wash must occur resection . Slides must available central cytology review . 5 . Patient ECOG performance status 02 . 6 . Patient adequate bone marrow , hepatic , renal function within 4 week Day 0 . 7 . Patient read understood inform consent form willing able give inform consent . 8 . Patient fully understand requirement study willing comply study visit assessment . 9 . If woman childbearing potential ( WCBP ) , patient negative blood pregnancy test Screening visit . For purpose study , WCBP define postpubescent female , unless postmenopausal least 2 year , surgically sterile , sexually inactive . 10 . If patient WCPB male patient female partner childbearing potential , must willing avoid pregnancy use adequate method contraception 2 week 4 week last study drug treatment . Adequate contraception define follow : 2 barrier method 1 barrier method spermicide intrauterine device . 1 . Patient evidence muscleinvasive disease ( i.e. , T2 high ) 2 . In Investigator 's opinion , patient able hold instillation least 1 hour . 3 . In Investigator 's opinion , patient tolerate intravesical administration intravesical surgical manipulation . 4 . Patient receive radiation therapy pelvis within 12 month first study drug treatment . 5 . Patient require perioperative intravesical chemotherapy . 6 . Patient history malignancy upper urinary tract . 7 . Patient bone marrow impairment evidence : Hemoglobin &lt; 9.0 g/dL Absolute neutrophil count ( ANC ) &lt; 1.5×109/L Platelet count &lt; 120×109/L . 8 . Patient renal impairment , evidence : Serum creatinine &gt; 2× upper limit normal ( ULN ) , and/or Calculated creatinine clearance &lt; 40 mL/min . 9 . Patient liver function abnormality , evidence : Total bilirubin &gt; 1.5×ULN , Aspartate aminotransferase ( AST ) /Alanine aminotransferase ( ALT ) &gt; 2.5×ULN . 10 . Patient bleed disorder , evidence international normalized ratio ( INR ) &gt; 1.5×ULN . 11 . Patient known positive human immunodeficiency virus ( HIV ) active hepatitis B C infection . 12 . Patient clinically significant active infection time first study drug treatment . 13 . Patient medical psychiatric condition , Investigator 's opinion , might impair patient 's wellbeing preclude adherence protocol complete study per protocol . 14 . Patient suspect hypersensitivity imidazoquinoline compound , poloxamer 407 , hydroxy propyl betacyclodextrin , lactic acid . 15 . If female , patient pregnant breast feeding . 16 . Patient participate protocol involve administration investigational agent within 3 month Day 0 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>bladder cancer</keyword>
	<keyword>carcinoma situ</keyword>
	<keyword>non muscle invasive bladder cancer</keyword>
</DOC>